Introduction: Although programmed cell death 1 (PD-1)/ programmed death ligand 1 (PD-L1) inhibitors have shown some efficacy in treating advanced NSCLC, their benefits are limited to only a subset of patients. Advanced NSCLC is generally treated with a chemotherapy and immunotherapy series. Here we evaluated whether PD-1/PD-L1 inhibitors affect the antitumor effects of salvage chemotherapy administered after immunotherapy (SCAI) in patients with NSCLC.
Introduction
Many anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have demonstrated efficacy for treating advanced NSCLC [1] [2] [3] [4] [5] and have recently been approved as first-line or subsequent-line therapies for advanced NSCLC in many countries. Because the incorporation of PD-1/PD-L1 inhibitors into chemotherapy series for advanced NSCLC is anticipated to become more common, interest has grown in characterizing interactions between immunotherapy and chemotherapy, particularly with respect to their antitumor effects.
Interestingly, unique survival patterns were observed in previous trials of PD-1/PD-L1 inhibitors. Although patients treated with PD-1/PD-L1 inhibitors showed little or no benefit in terms of progression-free survival (PFS) compared with in the chemotherapy arm, a significant benefit in overall survival was observed. 3, 4 This finding indicates that the PD-1/PD-L1 inhibitor arm had superior PFS for postprogression therapy compared with the chemotherapy arm. Regarding the underlying mechanism of this phenomenon, it is reasonable to infer that the antitumor effects of anti-PD-1/PD-L1 inhibitors are still acting or may even increase the effects of subsequent chemotherapy, even when tumor size increases during the previous immunotherapy.
One concern regarding the use of immunotherapy and chemotherapy in combination has been that chemotherapy could eliminate many immune cells, thereby antagonizing the immunotherapy effects. However, it was demonstrated clinically that chemotherapy does not have an antagonistic effect on combination therapy. Specifically, patients receiving a concurrent pembrolizumab plus chemotherapy regimen for advanced NSCLC showed higher response rates than those receiving chemotherapy alone (55% versus 29%). 6 Although many preclinical studies have supported a synergistic interaction between immunotherapy and chemotherapy, 7, 8 until now, there have been very few clinical studies on the antitumor effects of salvage chemotherapy administered after immunotherapy (SCAI). 9, 10 In the current study, we evaluated whether chemotherapy administered after treatment with PD-1/ PD-L1 inhibitors yielded improved antitumor effects compared with those usually expected. For more objective evaluation, we compared the response rates and PFS between SCAI and the last chemotherapy administered before the immunotherapy (LCBI) in the same NSCLC study population.
Material and Methods

Study Design and Patients
This retrospective study included (1) patients treated with anti-PD-1/PD-L1 inhibitors for advanced NSCLC, (2) patients who exhibited disease progression after treatment with anti-PD-1/PD-L1 inhibitors and who received SCAI, and (3) patients for whom SCAI efficacy data were available. Patients were excluded if small molecule inhibitors or targeted therapies were used in the period between PD-1/PD-L1 inhibitor treatment and SCAI.
To more objectively evaluate the clinical outcomes for SCAI, we compared the response rates and PFS with those for LCBI. For example, if a patient was treated with pemetrexed plus cisplatin as a first-line therapy followed by second-line docetaxel, third-line nivolumab, and fourth-line gemcitabine therapy, gemcitabine chemotherapy would be defined as the SCAI and docetaxel therapy would be the LCBI.
Statistical Analyses
The primary end point was the objective response rate (ORR), which was reassessed by the investigators according to the guideline of the Response Evaluation Criteria in Solid Tumors. The secondary end point was PFS, which was defined as time from the start of SCAI to disease progression or death due to any cause.
We compared ORR and PFS between the SCAI and LCBI treatments by using the chi-square test and logrank test, respectively. Given that platinum-based chemotherapy and non-platinum-based chemotherapy have different efficacies for treating NSCLC, we additionally compared SCAI and LCBI efficacy data by stratifying into platinum doublet chemotherapy and nonplatinum monotherapy groups.
All statistical analyses were performed using the SPSS 19 software package (IBM Corp, Armonk, NY). Differences with a p value less than 0.05 were regarded as significant. The study was approved by the institutional review board of the Samsung Medical Center. The requirement of informed consent was waived as the study was based in the retrospective analyses of existing administrative and clinical data.
Results
Baseline Characteristics
From October 2013 to March 2017, 309 patients received anti-PD-1/PD-L1 inhibitors for advanced NSCLC. As of data lockdown (May 2017), 212 patients had not received SCAI, nine had received tyrosine kinase inhibitors as the first therapy after immunotherapy, four were enrolled in the blind randomized study, and 11 had no available SCAI efficacy data. Thus, 73 patients met the inclusion criteria and were included in the analyses (Fig. 1) . The baseline characteristics of the patients are described in Table 1 . In all, 34 patients received nivolumab, 30 received pembrolizumab, 4 received durvalumab, 3 received avelumab, 1 received durvalumab plus tremelimumab, and 1 received atezolizumab. SCAI was administered as a second-line therapy (n ¼ 10), thirdline therapy (n ¼ 38), fourth-line therapy (n ¼ 10), fifth-line therapy (n ¼ 8), and sixth-line therapy (n ¼ 7), counting immunotherapy into the line of therapy.
Objective SCAI and LCBI Response Rates
Of the 73 patients, 10 received anti-PD-1/PD-L1 inhibitors as the first-line therapy; LCBI data were not available for these patients. Thus, 73 had SCAI data and 63 had LCBI data. Among the 73 patients treated with SCAI, an objective response was achieved in 39 patients, yielding an ORR of 53.4%. The ORR for LCBI was 34.9% (22 of 63 [p ¼ 0.03]) ( Table 2 and Fig. 2 ).
ORR according to Chemotherapy Regimen
Of the 73 SCAI regimens, 24 were platinum doublet chemotherapy and 49 were nonplatinum monotherapy.
Of the 63 LCBI regimens, 43 were platinum doublet chemotherapy and 20 were nonplatinum monotherapy. The ORRs for platinum doublet LCBI and SCAI therapies were 39.5% (17 of 43) and 66.7% (16 of 24), respectively (p ¼ 0.03). The ORRs for LCBI and SCAI nonplatinum monotherapies were 25.0% (five of 20) and 46.9% (23 of 49), respectively (p ¼ 0.09) (see Table 2 and Fig. 2 ).
In addition, we compared ORRs according to SCAI and LCBI chemotherapy regimen. Across all regimens, the ORRs for SCAI were higher than those for LCBI. In particular, the ORR of gemcitabine-based LCBI was different from that of gemcitabine-based SCAI. Gemcitabine regimens were used in 17 patients as LCBI regimens (gemcitabine/platinum in 13 patients and gemcitabine in 4) and in 22 patients as SCAI regimens (gemcitabine/platinum in 16 patients and gemcitabine in 6). The ORRs of gemcitabine-based LCBI and SCAI were 29.4% (five of 17) and 63.6% (14 of 22), respectively (p ¼ 0.04) (see Fig. 2 ). The ORR for gemcitabine/platinum doublet SCAI chemotherapy was 75% (12 of 16), whereas the ORR for gemcitabine/platinum doublet LCBI chemotherapy was 38.5% (five of 13) (p ¼ 0.04). Figure 3 shows that the axillary and abdominal lymph nodes were dramatically decreased when gemcitabine/ carboplatin chemotherapy was administered after nivolumab therapy.
PFS and Overall Survival
There was no difference in PFS between the SCAI and LCBI regimens. The median PFS times for SCAI and LCBI were 4.2 months and 4.7 months, respectively (p ¼ 0.84) (see Table 2 and Fig. 3 ). In the subset analysis according to platinum-based therapy, the median PFS times for platinum doublet SCAI and LCBI were 4.7 months and 4.5 months, respectively (p ¼ 0.86) and the median PFS times for nonplatinum SCAI and LCBI monotherapy were 3.8 months and 3.5 months, respectively (p ¼ 0.56) (see Table 2 ).
The median overall survival, the interval from start of SCAI to death, was 8.1 months, and the median overall survival times for platinum doublet and nonplatinum were 10.9 months and 6.5 month, respectively (p ¼ 0.27).
Relationship with Previous PD-1/PD-L1 Inhibitor Therapy
The antitumor responses of PD-1/PD-L1 inhibitors were partial response (n ¼ 7), stable disease (n ¼ 33), and progressive disease (n ¼ 33). The ORR of SCAI was 71.4% in patients who had previously achieved a partial response to PD-1/PD-L1 inhibitors, whereas the ORR of SCAI was 51.5% in all other patients (p ¼ 0.31).
The median duration of treatment with PD-1/PD-L1 inhibitors was 12.7 weeks (95% confidence interval: 12.4-17.5). There was no difference in the ORR of SCAI according to the duration of PD-1/PD-L1 inhibitor therapy. When patients were classified according to duration of PD-1/PD-L1 therapy, the ORR of SCAI in patients who were treated with PD-1/PD-L1 inhibitors for less than 12 weeks was 59.4% (19 of 32), whereas it was 48.8% (20 of 41) in patients who were treated with PD-1/PD-L1 inhibitors for 12 weeks or longer (p ¼ 0.36).
The median interval from the last infusion of PD-1/ PD-L1 inhibitors to the start of SCAI was 5.5 weeks (95% confidence interval: 3.8-7.6). The ORR of SCAI in patients with an interval of less than 4 weeks was 53.3% (24 of 45). Similarly, the ORR of SCAI in patients with an interval of 4 weeks or longer was 53.6% (15 of 28) (p ¼ 0.98).
Discussion
Although PD-1/PD-L1 inhibitors are efficacious for treating NSCLC, only 20% of all patients are projected to benefit directly from PD-1/PD-L1 inhibitors in terms of objective response. 3, 5, 11 Although it has been shown that responders to immunotherapy have longer response durations, the overall survival benefits of PD-1/PD-L1 inhibitors compared with chemotherapy were much greater than expected. 3, 5, 11 The results presented here potentially explain why PD-1/PD-L1 inhibitors are associated with significant gain in overall survival, even though the inhibitors did not appear to be beneficial for ORR or PFS. Our data indicate that the increased antitumor effect of SCAI may contribute, at least in part, to the observed improved overall survival.
Our study is supported by recent reports. A retrospective analysis of 39 patients with NSCLC receiving chemotherapy after administration of immune checkpoint inhibitors reported an unexpectedly high ORR of SCAI (30.7%). 9 Another retrospective study reported that patients (n ¼ 67) with prior exposure to PD-1/PD-L1 inhibitors were three times more likely to achieve a partial response to salvage chemotherapy compared with patients (n ¼ 15) who had not been treated with PD-1/PD-L1 inhibitors. 10 The mechanism by which standard-dose chemotherapy exerts positive immunomodulatory effects has been investigated. 7 First, chemotherapy induces immunogenic cell death, which leads to the concomitant release of tumor antigens and the emission of dangerassociated molecular patterns in the tumor microenvironment during cell death. Second, chemotherapy drugs can modulate the activity of distinct immune cell subsets by enhancing antigen presentation, upregulating expression of costimulatory molecules, or downregulating inhibitory checkpoint molecules such as PD-L1. 12 Although it has been suggested that chemotherapy and immunotherapy might have synergistic effects, it was unclear which treatment sequence achieves optimal antitumor effects. The KEYNOTE-024 study randomized advanced patients with NSCLC into either the pembrolizumab arm or the pemetrexed/carboplatin arm as first-line therapy, and cross-over was allowed on disease progression.
2 As a result, many patients who had progressed during first-line chemotherapy or pembrolizumab received second-line pembrolizumab or chemotherapy, respectively. Recently, a comparison of the combined PFS for the first-and second-line therapy (PFS2) between the two arms was reported. 13 It showed that the PFS2 for first-line pembrolizumab followed by subsequent second-line chemotherapy was significantly longer than that of first-line chemotherapy followed by pembrolizumab (median PFS2 of 18.3 versus 8.4 months [p < 0.01]). These clinical data strongly suggest that immunotherapy followed by chemotherapy is a better treatment sequence than chemotherapy followed by immunotherapy, which is compatible to our data.
One preclinical study supports the superiority of the sequence of immunotherapy followed by chemotherapy to the sequence of chemotherapy followed by immunotherapy. Specifically, mice bearing lung cancer tumors were administered intratumorally with adenovirusexpressing interferon alfa (Ad-IFN-a), followed by intravenously administered gemcitabine and cisplatin chemotherapy.
14 The tumors shrunk markedly with this therapy sequence, whereas the Ad-IFN-a alone, chemotherapy alone, and chemotherapy followed by Ad-IFN-a therapies induced only slight tumor shrinkage.
Across all chemotherapy regimens, the ORR of SCAI was higher than that of LCBI. This difference was particularly great for the gemcitabine-based regimens. The immunomodulatory effect of gemcitabine has been well investigated. Gemcitabine-induced tumor cell apoptosis increases cross-presentation of tumor antigens to immune cells, leading to increased levels of antigen-specific central-memory T cells, systemic CD8-positive T cells, and intratumoral CD8-positive T cells. 14, 15 In addition, gemcitabine administered after immunotherapy has been shown to prevent the increase of immune-inhibitory cells induced by immunotherapy and to augment leukocyte trafficking to tumor sites. 14 However, this small retrospective study is not powered to determine which chemotherapeutic regimen is best for SCAI; future clinical studies with larger sample sizes could help address this question.
Although we observed an increased ORR for SCAI, the PFS for SCAI was similar to that of LCAI. One possible explanation for the observed similarity of PFS between SCAI and LCAI may have to do with the lack of continuity of the immunomodulatory effects of chemotherapy. Although the positive effects of PD-1/PD-L1 inhibitors can affect the initial response to SCAI, these effects are likely not persistent. If this hypothesis is true, this limitation can be overcome by continuing PD-1/PD-L1 inhibitor therapy in patients while adding chemotherapy to the regimen (i.e,. when disease progression appears while the patient is taking PD-1/PD-L1 inhibitors alone). This treatment strategy is currently being investigated by an independent research group (ClinicalTrials.gov identification number: NCT03083808).
